Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Wasserman

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Vascular Medicine (London, England)|July 3, 2004
Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implicationsScott M Wasserman, James N Topper
Expert Review of Cardiovascular Therapy|April 1, 2015
Evolocumab (AMG 145) for primary hypercholesterolemiaGisle Langslet, Maurice Emery, Scott M Wasserman
Circulation|June 5, 2013
Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to knowIan N Foltz, Margaret Karow, Scott M Wasserman
The New England Journal of Medicine|August 28, 2014
Evolocumab in hyperlipidemiaDirk J Blom, Scott M Wasserman, Evan A Stein
The New England Journal of Medicine|August 22, 2015
PCSK9 Inhibitors and Cardiovascular EventsMarc S Sabatine, Scott M Wasserman, Evan A Stein
The Journal of Thoracic and Cardiovascular Surgery|March 11, 2008
Successful lysis of an aortic prosthetic valve thrombosis with a dosing regimen for peripheral artery and bypass graft occlusionsPatricia K Nguyen, Scott M Wasserman, James I Fann, et al.
The American Journal of Cardiology|February 5, 2013
Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular eventsJohn C LaRosa, Terje R Pedersen, Ransi Somaratne, et al.
Pharmacology & Therapeutics|July 22, 2014
PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levelsA David Marais, Jae B Kim, Scott M Wasserman, et al.
European Journal of Cardiovascular Nursing|December 7, 2007
Psychometric properties of a Swedish version of the Kansas City Cardiomyopathy Questionnaire in a Chronic Heart Failure populationHarshida Patel, Inger Ekman, John A Spertus, et al.
The American Journal of Cardiology|November 9, 2015
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular RiskArihiro Kiyosue, Narimon Honarpour, Christopher Kurtz, et al.
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Vascular Medicine (London, England)|July 3, 2004
Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implicationsScott M Wasserman, James N Topper
Expert Review of Cardiovascular Therapy|April 1, 2015
Evolocumab (AMG 145) for primary hypercholesterolemiaGisle Langslet, Maurice Emery, Scott M Wasserman
Circulation|June 5, 2013
Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to knowIan N Foltz, Margaret Karow, Scott M Wasserman
The New England Journal of Medicine|August 28, 2014
Evolocumab in hyperlipidemiaDirk J Blom, Scott M Wasserman, Evan A Stein
The New England Journal of Medicine|August 22, 2015
PCSK9 Inhibitors and Cardiovascular EventsMarc S Sabatine, Scott M Wasserman, Evan A Stein
The Journal of Thoracic and Cardiovascular Surgery|March 11, 2008
Successful lysis of an aortic prosthetic valve thrombosis with a dosing regimen for peripheral artery and bypass graft occlusionsPatricia K Nguyen, Scott M Wasserman, James I Fann, et al.
The American Journal of Cardiology|February 5, 2013
Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular eventsJohn C LaRosa, Terje R Pedersen, Ransi Somaratne, et al.
Pharmacology & Therapeutics|July 22, 2014
PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levelsA David Marais, Jae B Kim, Scott M Wasserman, et al.
European Journal of Cardiovascular Nursing|December 7, 2007
Psychometric properties of a Swedish version of the Kansas City Cardiomyopathy Questionnaire in a Chronic Heart Failure populationHarshida Patel, Inger Ekman, John A Spertus, et al.
The American Journal of Cardiology|November 9, 2015
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular RiskArihiro Kiyosue, Narimon Honarpour, Christopher Kurtz, et al.
Pageof 10